Norges Bank
SYRE icon

Norges Bank’s Spyre Therapeutics SYRE Stock Holding History

Norges Bank’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-70,843
Closed -$1.67M – 1953
2024
Q2 		$1.67M Buy
+70,843
New +$2.39M ﹤0.01% 1750
2017
Q1 		– Sell
-2,528
Closed -$275K – 2178
2016
Q4 		$275K Hold
2,528
– – ﹤0.01% 2136
2016
Q3 		$387K Sell
2,528
-272
-10% -$37.8K ﹤0.01% 2119
2016
Q2 		$340K Buy
+2,800
New +$537K ﹤0.01% 2138

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank's SYRE Position: Q3 2024 in Review

Norges Bank sold out of Spyre Therapeutics (SYRE) in Q3 2024, closing a stake of 70,843 shares — an estimated $1.67M sold.

Norges Bank first reported a position in SYRE in Q2 2016 and held it in 4 quarters. The position peaked at $1.67M in Q2 2024. 119 funds tracked by Wall St. Rank hold SYRE as of Q3 2024.

  • Norges Bank reported no remaining Spyre Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Norges Bank sold 70,843 Spyre Therapeutics shares in Q3 2024, an estimated $1.67M.
  • Norges Bank first reported a position in Spyre Therapeutics in Q2 2016 and held it in 4 quarters.
  • Norges Bank's Spyre Therapeutics position peaked at $1.67M in Q2 2024.
  • 119 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2024.

Based on Norges Bank's 13F filing for Q3 2024, filed 13 Nov 2024.